Drug Profile
HRC 102
Alternative Names: HML 110Latest Information Update: 16 Sep 2019
Price :
$50
*
At a glance
- Originator Hemosol Corp
- Developer Therapure Biopharma
- Class
- Mechanism of Action Oxygen carriers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hypoxia
Most Recent Events
- 30 Jan 2004 HRC 102 is available for licensing (http://hrc.hemosol.com)
- 03 Jan 2002 Preclinical development for Acute hypoxia in Canada (Unknown route)